TY - JOUR T1 - Top 10 research priorities for people living with pulmonary fibrosis, their caregivers, healthcare professionals and researchers JF - Thorax JO - Thorax SP - 575 LP - 581 DO - 10.1136/thoraxjnl-2020-215731 VL - 76 IS - 6 AU - Gabriella Tikellis AU - Allison Tong AU - Joanna Y T Lee AU - Tamera J. Corte AU - Alison J Hey-Cunningham AU - Michael Bartlett AU - Tonia Crawford AU - Ian Glaspole AU - John Price AU - Jamie Maloney AU - Anne E Holland Y1 - 2021/06/01 UR - http://thorax.bmj.com/content/76/6/575.abstract N2 - Introduction People with pulmonary fibrosis (PF) experience a high symptom burden, reduced quality of life and a shortened lifespan. Treatment options are limited and little is known about what patients, caregivers and healthcare professionals (HCPs)/researchers consider as the most important research priorities. This study aimed to identify the top 10 research priorities for PF across all stakeholders.Methods Participants included people with PF, caregivers and HCPs/researchers involved with PF. The research priority setting exercise involved three stages: (1) identifying priorities using an open-ended questionnaire and thematic analysis, (2) development of specific research questions at a face-to-face workshop, and (3) online ranking of research questions to identify the top 10 research priorities using nominal group ranking method.Results 196 participants completed stage 1 generating 560 questions and 14 research themes were identified. Stage 2 involved 32 participants and generated 53 indicative questions from which 39 were used for the final ranking. Stage 3 was completed by 270 participants. The top ranked priorities focussed on medications to reverse scarring in the lungs (ranked 1st), improving lung function (ranked 2nd, 6th and 8th), interventions aimed at alleviating symptoms (ranked 5th and 7th), prevention of PF (ranked 3rd and 4th) and the best exercise programme for PF (ranked 10th). There was good consensus among patients/carers and HCPs/researchers on the top 10 priorities, however, causes of acute exacerbations and early diagnosis for improving survival, was ranked higher by HCPs/researchers.Conclusion Interventions for preserving lung health and alleviation of symptom burden were top research priorities for PF stakeholders.Data sharing not applicable as no data sets generated and/or analysed for this study. Data is qualitative rather than quantitative and its use has been approved for this study only. ER -